Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors
- 14 June 2006
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (16), 4174-4177
- https://doi.org/10.1016/j.bmcl.2006.05.096
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1Bioorganic & Medicinal Chemistry Letters, 2006
- Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part IBioorganic & Medicinal Chemistry Letters, 2006
- Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2Bioorganic & Medicinal Chemistry Letters, 2006
- Emerging anti-HIV drugsEmerging Drugs, 2005
- New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infectionsCurrent Opinion in Pharmacology, 2004
- ANTI-HIV CHEMOTHERAPY: CURRENT STATE OF THE ARTMedicinal Chemistry Research, 2004
- Novel Benzophenones as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1Journal of Medicinal Chemistry, 2004
- Delavirdine Mesylate, a Potent Non-Nucleoside HIV-1 Reverse Transcriptase InhibitorAdvances in experimental medicine and biology, 1996
- L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1995
- Inhibition of Human Immunodeficiency Virus Type I (HIV-I) Replication by the Dipyridodiazepinone BI-RG-587The Journal of Infectious Diseases, 1991